{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:41:23Z","timestamp":1768484483647,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ajog.2017.03.011","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T14:05:51Z","timestamp":1490105151000},"page":"59.e1-59.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utilization of gynecologic services in women with breast cancer receiving hormonal therapy"],"prefix":"10.1016","volume":"217","author":[{"given":"Jason D.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vrunda B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William M.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana I.","family":"Tergas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June Y.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Accordino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cande V.","family":"Ananth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred I.","family":"Neugut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2017.03.011_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A\u00a0randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2017.03.011_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.03.011_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","article-title":"Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14","volume":"86","author":"Fisher","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.03.011_bib4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","article-title":"Association of tamoxifen and uterine sarcoma","volume":"20","author":"Wickerham","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.03.011_bib5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centers' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.03.011_bib6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2017.03.011_bib7","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ajog.2004.12.083","article-title":"Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial","volume":"192","author":"Chalas","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.03.011_bib8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.AOG.0000450757.18294.cf","article-title":"Tamoxifen and uterine cancer. Committee opinion no. 601","volume":"123","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.03.011_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1005820115535","article-title":"Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients","volume":"47","author":"Bertelli","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ajog.2017.03.011_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-8258(03)00441-4","article-title":"Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen","volume":"91","author":"Fung","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.03.011_bib11","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.1999.17.7.2050","article-title":"Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening","volume":"17","author":"Love","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2017.03.011_bib12","unstructured":"Truven Health Analytics. MarketScan. Available at: http:\/\/truvenhealth.com\/your-healthcare-focus\/life-sciences\/marketscan-databases-and-online-tools. Accessed June 21,\u00a02015."},{"key":"10.1016\/j.ajog.2017.03.011_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ajog.2017.03.011_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.ajog.2017.03.011_bib15","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/cncr.29332","article-title":"Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors","volume":"121","author":"Chlebowski","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2017.03.011_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.1994.tb21761.x","article-title":"Tamoxifen and endometrial cancer","volume":"734","author":"Sismondi","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ajog.2017.03.011_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/gyno.1993.1118","article-title":"Role of prolonged stimulation of tamoxifen therapy in the etiology of endometrial sarcomas","volume":"49","author":"Altaras","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2017.03.011_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0140-6736(94)92692-1","article-title":"Risk of endometrial cancer after tamoxifen treatment of breast cancer","volume":"343","author":"van Leeuwen","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ajog.2017.03.011_bib19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1525-1497.2003.20724.x","article-title":"Meta-analysis of vascular and neoplastic events associated with tamoxifen","volume":"18","author":"Braithwaite","year":"2003","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.ajog.2017.03.011_bib20","doi-asserted-by":"crossref","first-page":"535.e1","DOI":"10.1016\/j.ajog.2011.06.067","article-title":"Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)","volume":"205","author":"Runowicz","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.03.011_bib21","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/AOG.0000000000001484","article-title":"Aromatase inhibitors in gynecologic practice. Committee opinion no. 663","volume":"127","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.03.011_bib22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1046\/j.1469-0705.1995.06020116.x","article-title":"Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study","volume":"6","author":"Achiron","year":"1995","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.ajog.2017.03.011_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0029-7844(97)00591-7","article-title":"Uterine side effects of tamoxifen: a need for systematic pretreatment screening","volume":"91","author":"Berliere","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"Suppl","key":"10.1016\/j.ajog.2017.03.011_bib24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0959-8049(00)00217-3","article-title":"Identification of women at high risk of developing endometrial cancer on tamoxifen","volume":"36","author":"Berliere","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2017.03.011_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0301-2115(01)00516-4","article-title":"Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring","volume":"101","author":"Vosse","year":"2002","journal-title":"Eur J Obstet Gynecol Reprod Biol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817304222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937817304222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:13:18Z","timestamp":1757589198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937817304222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0002937817304222"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2017.03.011","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of gynecologic services in women with breast cancer receiving hormonal therapy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2017.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}